Liquidity (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Jan. 26, 2018 |
Jun. 30, 2018 |
Mar. 31, 2018 |
Jun. 30, 2018 |
Dec. 31, 2017 |
|
| Accumulated deficit | $ 89,462,837 | $ 89,462,837 | $ 65,698,101 | ||
| Amount received upon achievement | 12,500,000 | ||||
| Cash and cash equivalents | 64,676,538 | 64,676,538 | $ 62,537,495 | ||
| 2018 CFF Award [Member] | |||||
| Amount received for development award | $ 25,000,000 | ||||
| Phase 2b Clinical Trial [Member] | Investment Agreement [Member] | |||||
| Amount received upon achievement | $ 6,250,000 | $ 6,250,000 | $ 12,500,000 | ||
| X | ||||||||||
- Definition Amount received for development award. No definition available.
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of consideration recognized during the period for the milestone or milestones. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|